Antallet af frafald i TARGET grundet ødem var ikke signifikant forskelligt mellem lumiracoxib (43) og NSAID (55).
The number of discontinuations in TARGET due to oedema was not significantly different between lumiracoxib (43) and NSAIDs (55).